ES2196069T3 - Derivados morfinoides condensados con heterociclos. - Google Patents

Derivados morfinoides condensados con heterociclos.

Info

Publication number
ES2196069T3
ES2196069T3 ES95925855T ES95925855T ES2196069T3 ES 2196069 T3 ES2196069 T3 ES 2196069T3 ES 95925855 T ES95925855 T ES 95925855T ES 95925855 T ES95925855 T ES 95925855T ES 2196069 T3 ES2196069 T3 ES 2196069T3
Authority
ES
Spain
Prior art keywords
morfinoid
heterocicles
derivatives condensed
condensed
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95925855T
Other languages
English (en)
Inventor
Giulio Dondio
Silvano Ronzoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of ES2196069T3 publication Critical patent/ES2196069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LOS COMPUESTOS DE FORMULA (I), SON AGONISTAS Y ANTAGONISTAS SELECTIVOS PARA OPIODES TIPO DELTA, Y SON UTILES COMO ANALGESICOS Y PARA EL TRATAMIENTO DE ALTERACIONES NEUROLOGICAS DE CARACTER GENERAL.
ES95925855T 1994-07-14 1995-07-07 Derivados morfinoides condensados con heterociclos. Expired - Lifetime ES2196069T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI941463A IT1270612B (it) 1994-07-14 1994-07-14 Derivati eterociclo-condensatori di morfinoidi

Publications (1)

Publication Number Publication Date
ES2196069T3 true ES2196069T3 (es) 2003-12-16

Family

ID=11369271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95925855T Expired - Lifetime ES2196069T3 (es) 1994-07-14 1995-07-07 Derivados morfinoides condensados con heterociclos.

Country Status (19)

Country Link
US (1) US5981540A (es)
EP (1) EP0770081B1 (es)
JP (1) JP3480936B2 (es)
CN (1) CN1051086C (es)
AT (1) ATE236169T1 (es)
AU (1) AU686413B2 (es)
BR (1) BR9508406A (es)
CA (1) CA2194877A1 (es)
CZ (1) CZ9897A3 (es)
DE (1) DE69530205T2 (es)
ES (1) ES2196069T3 (es)
HU (1) HUT76812A (es)
IT (1) IT1270612B (es)
MX (1) MX9700373A (es)
NO (1) NO315119B1 (es)
NZ (1) NZ289858A (es)
PL (1) PL182747B1 (es)
WO (1) WO1996002545A1 (es)
ZA (1) ZA955782B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
AR005423A1 (es) * 1996-01-10 1999-06-23 Smithkline Beecham Spa Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados.
US6103722A (en) * 1997-07-23 2000-08-15 The Medical College Of Wisconsin Research Foundation Inc. Ischemic preconditioning
IT1312083B1 (it) * 1999-04-20 2002-04-04 Smithkline Beecham Spa Derivati morfinoidi, procedimento per la loro preparazione e loroimpiego terapeutico.
US7015326B1 (en) * 1999-08-13 2006-03-21 Southern Research Institute Pyridomorphinans, thienomorphinans and use thereof
WO2001012197A1 (en) * 1999-08-13 2001-02-22 Southern Research Institute Pyridomorphinans, thienomoprhinans and use thereof
US6465479B1 (en) 1999-08-13 2002-10-15 Southern Research Institute Pyridomorphinans and use thereof
GB0025056D0 (en) * 2000-10-12 2000-11-29 Smithkline Beecham Spa Novel compounds
EP1660088A4 (en) * 2003-08-27 2009-04-29 Southern Res Inst PYRIDOMORPHINANES, PYRIDAZINOMORPHINANES AND USE THEREOF
US9163030B2 (en) 2012-05-02 2015-10-20 Southern Research Institute Heterocycle-fused morphinans, use thereof and preparation thereof
WO2014136305A1 (ja) * 2013-03-08 2014-09-12 学校法人北里研究所 モルヒナン誘導体
CA2952124A1 (en) * 2014-06-13 2015-12-17 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223507A (en) * 1992-01-21 1993-06-29 G. D. Searle & Co. Method of using opioid compounds as delta opioid selective agonist analgesics
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds

Also Published As

Publication number Publication date
PL318148A1 (en) 1997-05-12
ATE236169T1 (de) 2003-04-15
CZ9897A3 (en) 1997-07-16
CN1161041A (zh) 1997-10-01
WO1996002545A1 (en) 1996-02-01
NO970142L (no) 1997-03-12
AU686413B2 (en) 1998-02-05
AU2982495A (en) 1996-02-16
NZ289858A (en) 1998-01-26
JP3480936B2 (ja) 2003-12-22
DE69530205D1 (de) 2003-05-08
JPH10502657A (ja) 1998-03-10
NO970142D0 (no) 1997-01-13
IT1270612B (it) 1997-05-07
CN1051086C (zh) 2000-04-05
EP0770081A1 (en) 1997-05-02
MX9700373A (es) 1998-03-31
ITMI941463A1 (it) 1996-01-14
NO315119B1 (no) 2003-07-14
HUT76812A (en) 1997-11-28
ITMI941463A0 (it) 1994-07-14
EP0770081B1 (en) 2003-04-02
DE69530205T2 (de) 2004-02-05
ZA955782B (en) 1996-02-26
US5981540A (en) 1999-11-09
CA2194877A1 (en) 1996-02-01
HU9700073D0 (en) 1997-02-28
PL182747B1 (pl) 2002-02-28
BR9508406A (pt) 1997-12-23

Similar Documents

Publication Publication Date Title
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
UY28150A1 (es) Agentes terapeuticos
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
MX9203422A (es) Compuestos farmacologicamente activos para el sistema nervioso central.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2059841T3 (es) Nitro compuestos con actividad insecticida.
ES2188888T3 (es) Derivados morfinoides 8ii) con condensados con heterociclos.
GT199900056A (es) Nuevas dihidropirimidinas
ES505721A0 (es) Procedimiento de obtencion de una composicion a base de derivados de urea para el tratamiento de textiles.
ES2196069T3 (es) Derivados morfinoides condensados con heterociclos.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
AR226354A1 (es) Procedimiento para preparar el complejo cis-isocitrato(1,2-diamino ciclohexano)plation
ES2101858T3 (es) Derivados de geneserina como inhibidores de colinesterasa.
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
ES2123827T3 (es) Derivados del acido poliamidico con actividad antigastrina, un metodo para su preparacion y su uso farmaceutico.
ES2118818T3 (es) Tiazolin-2-onas aminoalquil-substituidas, su obtencion y empleo.
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias